Acepodia Stock

www.acepodia.comHealthcare / BioTech & PharmaFounded: 2014

Acepodia, founded in 2016, is a clinical-stage biotechnology company that develops cell therapies aiming to treat cancer patients. Through its unique Antibody-Cell Conjugation (ACC) technology that links tumor-targeting antibodies to immune effector cells, the company aims to improve outcomes for cancer patients due to broad accessibility and effectiveness of the treatments. Acepodia is headquartered in Alameda, California.

Register for Details

For more details on financing and valuation for Acepodia, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Acepodia.

Register Today

Acepodia investors also invested in these private companies

Ridgeback Capital
National Cancer Institute
Digital Mobile Venture
DEFTA Partners


Management Team

Sonny Hsiao Ph.D
Co-Founder, Chief Executive Officer, Chief Scientific Officer & President
Jennifer Wang Ph.D
Chief Operating Officer & Vice President, Quality
Harry Lam Ph.D
Chief Technical Officer & Executive Vice President of Technical Operations
Patrick Yang Ph.D

Board Members

Elona Baum
DEFTA Partners

Other companies like Acepodia in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Acepodia picks up strong hand to advance cell therapies in $100M series D
Acepodia is ready to ante up its bet on cell therapy after turning over a brand new $100 million series D financing that will support the biotech's pipeline of medicines for solid tumors and hematological cancers.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.